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Abstract
Nitric oxide (NO) is a free radical that plays an important role in modulating platelet adhesion and
aggregation. Platelets are a source of vascular NO, but since erythrocytes avidly scavenge NO, the
functional significance of platelet-derived NO is not clear. Our purpose was to determine if NO
from platelets affects platelet thrombus formation in the presence of anticoagulated whole blood
in an in vitro parallel plate flow system. We studied platelet adhesion and aggregation on a collagen
type III surface in the presence of physiologically relevant fluid mechanical shear stress. We found
that certain receptor mediated agonists (insulin and isoproterenol) caused a concentration
dependent reduction in thrombus formation at a shear rate of 1000 s-1. This effect was mediated
by NO since it was abolished in the presence of the NO inhibitor L-nitro-arginine-methyl-ester (L-
NAME). As expected, at venous levels of shear rate (100 s-1) neither of the agonists had any effect
on thrombus formation since platelet adhesion does not depend on activation at these low levels
of shear. Interestingly, at a shear rate of 2000 s-1 the addition of L-NAME caused an increase in
platelet coverage suggesting that shear, by itself, induces NO production by platelets. This is the
first demonstration of shear stress causing platelets to produce an inhibitor of platelet activation.
These results demonstrate that the development of a platelet thrombus is regulated in a complex
way and that platelets produce functionally significant amounts of NO even in the presence of
whole blood.
Introduction
Platelet activation and aggregation play an important role
in the development of cardiovascular disease, which is the
leading cause of death in the United States. Over the last
several years, enormous advances have been made in
understanding the molecular mechanisms that regulate
platelet function. A general paradigm has emerged that
endothelial cells synthesize and release substances that
inhibit platelet activation (e.g. nitric oxide and prostacyc-
lin) except near a site of vascular injury, while platelets
synthesize and release substances that promote further
platelet activation. In contrast to this paradigm, several
recent studies have suggested that, in the presence of cer-
tain agonists (IGF-1, adenosine diphosphate, insulin, and
isoproterenol), platelets will produce nitric oxide (NO), a
potent inhibitor of platelet activation [1-5]. Although
these studies clearly showed that platelets produce NO,
the physiological relevance of this NO is not clear since
NO is highly reactive, has a short half-life, and the rate of
NO production is difficult to quantify. Therefore, there is
a need to determine if the NO derived from platelets is
Published: 15 November 2004
Thrombosis Journal 2004, 2:11 doi:10.1186/1477-9560-2-11
Received: 19 April 2004
Accepted: 15 November 2004
This article is available from: http://www.thrombosisjournal.com/content/2/1/11
© 2004 Williams and Nollert; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Thrombosis Journal 2004, 2:11 http://www.thrombosisjournal.com/content/2/1/11
Page 2 of 11
(page number not for citation purposes)
sufficient to modulate platelet function and alter throm-
bus growth in the presence of whole blood.
Platelet-derived NO is synthesized by membrane-bound
endothelial-type nitric oxide synthase (eNOS). A com-
mon signaling mechanism shared by many eNOS ago-
nists is binding to a surface receptor, followed by
activation of phosphatidylinositol-3-kinase (PI3K), which
results in phosphorylation of eNOS at serine 1179
through Akt [6-8]. The activated eNOS converts L-arginine
to L-citrulline and produces NO as a result [9]. Nitric
oxide is a water soluble free radical that can bind to the
heme-soluble site of guanylate cyclase in platelets and
smooth muscle cells, which increases synthesis of cyclic
guanosine monophosphate (cGMP) [5,10]. cGMP can
bind to phosphodiesterase III (PDE III), which reduces
metabolism of cyclic adenosine monophosphate (cAMP)
[10]. Elevated levels of cGMP and cAMP can result in
increased activity of protein kinase G (PKG) and protein
kinase A (PKA), which inhibit protein kinase C (PKC)
activation and intracellular Ca2+ mobilization [5]. The
consequence of this signal transduction cascade is the
inhibition of platelet activation and the relaxation of vas-
cular smooth muscle resulting in blood vessel dilation.
As a small, hydrophilic free radical NO is highly diffusible
in the aqueous environment of the blood. However, it is
also highly reactive with a very short half-life estimated to
be only on the order of a few seconds [11] in the blood.
Previous studies that demonstrated NO production in
platelets were done in the absence of erythrocytes [2-4]. It
is still not clear if the amount of NO produced by plate-
lets, estimated at about 5 × 10-17 mole NO/platelet (deter-
mined by microelectrode in PRP for 2 minutes following
addition of 5 µM ADP), is sufficient to alter platelet func-
tion [1,2].
The purpose of our study was to determine if platelet-
derived NO plays a role in thrombus formation in the
presence of shear stress. We examined the effect of several
external factors on platelet thrombus formation, includ-
ing insulin, the β-adrenoceptor agonist isoproterenol, and
shear stress. Previous studies showed that insulin and iso-
proterenol both induced NO formation by platelets [3,4].
Shear stress is an important component of the environ-
ment of the platelets and can cause alterations in platelet
function, although the effect of shear on NO synthesis in
platelets is unknown [12]. Our aim was to show that
platelet-derived NO plays a direct role in inhibiting
thrombus formation to a vascular injury and can be stim-
ulated by different external agonists through a common
NO signaling pathway.
Results
Insulin and isoproterenol slow the growth rate of mural 
thrombi
Platelets from whole blood adhered avidly to the colla-
gen-coated surface in the presence of physiologically rele-
vant levels of fluid mechanical shear stress. Very little, if
any, platelets were detected on the albumin-coated por-
tion of the slide. Detectable levels of platelet adhesion
were evident within 20–30 seconds of the initiation of
blood flow over the surface. Platelet adherence occurred
predominantly at the interface between albumin and col-
lagen and increased as a function of time similar to results
that have been obtained by others using a similar system
[13-16] Representative images of platelet accumulation
on collagen at a shear rate of 1000 s-1 are shown in Figure
1. In these images, the flow was from left to right. The
albumin/collagen interface is clearly evident in the images
from later time points. At other shear rates, platelet accu-
mulation on the surface was also abundant as illustrated
in Figure 2A. These results are in qualitative agreement
with previously published results [13]. The slower rate of
platelet deposition at higher levels of shear has been
attributed [17] to the increased level of fluid mechanical
drag on the platelets preventing them from forming stable
attachments to the surface.
The effect of insulin and isoproterenol on mural throm-
bus formation was studied and the results are presented in
Figures 2B and 2C as the percent coverage of the collagen-
coated surface as a function of time. Increasing the con-
centration of either insulin (0, 100, 1000 pM) or isoprot-
erenol (0, 100, 1000 µM) at a shear rate of 1000 s-1
resulted in increasing inhibition of platelet accumulation
on the surface. Higher concentrations of either insulin or
isoproterenol had no additional affect on the extent of
platelet accumulation on the surface (data not shown).
Inhibition of thrombus formation was significant (p <
0.05) up to 6 minutes with 1000 pM insulin and up to 3
minutes with 1000 µM isoproterenol. Significance was
determined with SPSS using the Post Hoc test as described
in Methods.
Agonist induced reduction in thrombus formation depends 
on NO and shear rate
In order to investigate the mechanism of insulin and iso-
proterenol induced reduction in platelet accumulation on
a collagen surface, we perfused blood through the flow
chamber in the presence of agonist (either insulin or iso-
proterenol) as well as L-NAME, a specific inhibitor of
nitric oxide production. The results are presented in Fig-
ures 3C,3D for the shear rate of 1000 s-1. In the presence
of L-NAME as well as either insulin or isoproterenol,
thrombus formation is increased, returning to levels seen
in the absence of added agonist. This suggests a role for
nitric oxide in mediating the agonist induced reduction inThrombosis Journal 2004, 2:11 http://www.thrombosisjournal.com/content/2/1/11
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platelet accumulation on the surface. Platelet thrombus
formation on the surface at lower (100 s-1) and higher
(2000 s-1) levels of shear rate are shown in Figures 3A,3B
and 3E,3F respectively. At the lower, venous shear rate
(100 s-1) platelet accumulation on the surface is not signif-
icantly altered by either insulin (500 pM) or isoproterenol
(100 µM). Higher concentrations of either agonist had no
affect as well (data not shown). In addition, L-NAME by
itself or in combination with either agonist did not signif-
icantly affect platelet deposition on the surface (Figures
3A,3B). At the higher, arterial shear rate of 2000 s-1 (Fig-
ures 3E,3F), platelet accumulation was not significantly
reduced by either insulin (500 pM) and isoproterenol
(100 µM) as illustrated in Figures 3E,3F.
At the high shear rate of 2000 s-1 we observed a curious
result when the blood was treated with L-NAME but in the
absence of any agonist. The results are presented in Figure
Representative images of time-dependent platelet adhesion and aggregate formation on collagen type III Figure 1
Representative images of time-dependent platelet adhesion and aggregate formation on collagen type III. Single platelets and 
platelet aggregates adherent on the surface appear bright and were visualized using epi-fluorescence video microscopy. Plate-
lets adhered abundantly on the collagen surface, particularly near the upstream interface between collagen and albumin. No 
adhesion was observed on the albumin-coated surface. Flow was from left to right and the shear rate was 1000 s-1. These 
results are typical of 5 separate experiments.
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Dose dependence of thrombus formation Figure 2
Dose dependence of thrombus formation. The extent of platelet adhesion onto the surface, as assessed by the percentage of 
the collagen-coated surface covered by platelets, is shown as a function of time. Perfusions for shear [100 (■ ), 1000 (), 1500 
(● ), and 2000 (❍ ) s-1] were performed for 5 minutes (Figure 2A). Perfusions for control (■ ), insulin [100 (◆ ) and 1000 pM 
()] and isoproterenol [100 (▲ ) and 1000 µM ()] were performed at 1000 s-1 (Figures 2B-C) for 6 minutes. The results pre-
sented are mean ± s.e.m. of at least 5 experiments using 5 different blood donors.
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Reduction in thrombus growth rate depends on platelet derived NO Figure 3
Reduction in thrombus growth rate depends on platelet derived NO. Perfusions for control (■ ), insulin, 500 pM (◆ ), isoprot-
erenol, 100 µM (▲ ), and samples preincubated with L-NAME [insulin () and isoproterenol ()] were performed at 100, 
1000, and 2000 s-1 (Figures 3A-F). Results represent mean ± s.e.m. of at least five experiments with five separate blood donors.
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4. We found that in the presence of L-NAME, thrombus
formation increased either with (data not shown) or with-
out agonist present (Figure 4C). This result suggests a role
for nitric oxide in modulating the rate of platelet deposi-
tion onto a collagen surface at a shear rate of 2000 s-1 even
in the absence of insulin or isoproterenol.
Effect of insulin and isoproterenol on guanylate cyclase 
activity
We further investigated the mechanism of platelet derived
nitric oxide inhibition of thrombus formation by using
the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo [4,
3-a]quinozalin-1-one (ODQ), since the primary target of
NO in platelets is guanylate cyclase [18,19]. As illustrated
in Figure 5A, thrombus formation at 1000 s-1 and in the
presence of insulin was slightly increased by addition of
ODQ. No significant effect of ODQ on thrombus forma-
tion was observed with isoproterenol (Figure 5B) or in the
absence of agonist (Figure 5C). This is not surprising since
our other studies at this shear with isoproterenol (Figure
2D) or in the absence of agonist (Figure 3B) pointed out
that the effect on platelet thrombus formation was also
very small. Interestingly, we see that ODQ causes an
increase in thrombus formation at 2000 s-1 if either insu-
lin, isoproterenol, or no agonist is used (Figures
5D,5E,5F). This suggests that at 2000 s-1, guanylate cyclase
activation is occurring even in the absence of added exter-
nal agonists.
Discussion
The purpose of this study was to determine if nitric oxide
from platelets affects platelet function. Previous studies
have identified the vascular endothelium as the primary
source of NO in the blood. Only recently have platelets
been identified as an additional source of NO. The role of
platelet derived NO in modulating platelet function has
not been established. Most of the other studies that have
examined NO production by platelets were performed
with platelet rich plasma or with washed platelets. This
was required in order to increase the platelet concentra-
tion to the point where NO levels could be assessed. How-
ever, since these studies were performed in the absence of
erythrocytes, it is difficult to extrapolate the results to the
in vivo situation where hemoglobin in red cells efficiently
scavenges the nitric oxide free radical. Therefore, the
experiments in our current study were designed to
Effect of guanylate cyclase on platelet adhesion kinetics Figure 5
Effect of guanylate cyclase on platelet adhesion kinetics. Platelet coverage values for each study are the mean ± s.e.m of 4 sep-
arate experiments, each using a different donor. Perfusions were conducted at 1000 and 2000 s-1 (Figures 5A and 5B) for 6 
minutes with insulin, 500 pM (■ ), isoproterenol, 1000 µM (▲ ) and samples preincubated with guanylate cyclase inhibitor ODQ 
[insulin () and isoproterenol ()].
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Shear stress causes a slowing of thrombus growth rate that depends of platelet derived NO Figure 4
Shear stress causes a slowing of thrombus growth rate that depends of platelet derived NO. Platelet coverage values for each 
study are the mean ± s.e.m. of 5 separate experiments, each using a different donor. Perfusions for control (■ ) and L-NAME 
() samples were conducted at 100, 1000, and 2000 s-1 (Figures 4A-C) for 6–10 minutes.
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measure platelet function in a vascular injury model
where the platelets remain in whole blood.
Several recent studies have demonstrated that platelets
produce NO in response to agonists including insulin,
isoproterenol, and ADP [2,4]. Using an in vitro parallel
plate flow chamber, we show in this study that the rate of
mural thrombus growth on a collagen III surface is mod-
ulated by platelet derived NO. This is the first study to
show that platelet derived NO can alter platelet function
in whole blood. We found that insulin, isoproterenol, and
shear stress could, under the right circumstances, modu-
late platelet function through an NO-mediated mecha-
nism. In fact, we found that at a shear rate of 2000 s-1, but
not at either 100 or 1000 s-1, platelet adhesion to the sur-
face was increased in the presence of L-NAME, an
inhibitor of nitric oxide production. This result suggests
that platelets produce nitric oxide at higher shear rates but
not at lower levels of fluid mechanical stress. This result is
consistent with the observation that elevated levels of
shear stress can cause platelet activation [20,21] and that
nitric oxide production may be a common feature of
platelet activation regardless how activation is initiated
[8,22].
At the low, venous level of shear (100 s-1) that we tested,
platelet derived NO did not appear to play a role in mod-
ulating platelet accumulation on the surface. This result
was not surprising due to the many types of adhesion
receptors on platelets that function well in a low shear
environment. The primary platelet receptors for collagen
III on a surface are GPVI and α2β1 [23,24]. Additionally,
the GPIb-V-X receptor complex can mediate platelet adhe-
sion through interactions with soluble and surface associ-
ated von Willebrand Factor [25]. Because of the
interaction with collagen, the platelets become activated.
Activation induces an extensive series of intracellular sig-
naling events to take place, resulting in the conversion of
the integrins α2β1 and  αIIbβ3 into a high affinity state
through a process termed inside-out signaling. In this
high affinity state, these integrins are capable of
supporting platelet-platelet interactions and promoting
thrombus growth. Therefore, platelet adhesion at low lev-
els of shear rate can be mediated by a number of different
adhesion molecules, some of which do not require plate-
let activation. Our results are consistent with this model
since we found that platelet derived nitric oxide did not
inhibit the rate of thrombus growth at these low, venous
levels of shear rate.
At intermediate shear (1000 s-1), integrins α2β1 and αIIbβ3
play a more significant role in platelet adhesion and
recruitment. These platelet integrins are essential for
thrombus formation at intermediate to high shear [26].
Furthermore, these integrins must become activated, that
is convert into a high affinity conformation, in order for
them to be capable of supporting adhesion at these high
levels of shear [27]. This requires intracellular signal trans-
duction events and platelet activation, a process that is
inhibited by nitric oxide. Our results (Figures 1A and 1B)
suggest that insulin and, to a lesser extent, isoproterenol
can both cause a decrease in the rate of growth of thrombi
and that this decrease is concentration dependent.
Furthermore, we showed that the mechanism of this inhi-
bition of thrombus growth involves a nitric oxide/guanyl-
yate cyclase pathway (Figures 2B and 4A).
Our results with the inhibitors of platelet signaling, L-
NAME and ODQ, are consistent with previous studies. L-
NAME completely abolished the anti-thrombotic effects
of both insulin and isoproterenol at a shear rate of 1000 s-
1 showing that these agonists act through a pathway that
involves nitric oxide. ODQ was effective in inhibiting the
action of insulin, but was less effective in inhibiting the
action of isoproerenol. This result is consistent with ear-
lier findings that suggested that isoproterenol inhibited
platelet activation partially through a mechanism involv-
ing adenylate cyclase [28] rather than guanylyate cyclase.
The results we present with the inhibitors L-NAME and
ODQ at the highest shear rate, 2000 s-1 (Figures 2C, 4C,
and 4D) failed to demonstrate a role for platelet-derived
NO or signaling through guanylyate cyclase. However, in
the absence of added agonist, shear stress, by itself was
able to induce platelets to produce NO (Figures 3C and
5B). Although there has been no previous evidence for
shear-dependent NO production in platelets, both in vitro
and in vivo studies have demonstrated shear stress upreg-
ulates eNOS activity in endothelial cells [7,29]. The mech-
anism is not completely understood but involves
cytoskeletal proteins and the activation of a series of
kinases including PI3 kinase and Akt as well as Hsp90
[30,31]. A similar pathway for the activation of eNOS has
been recently characterized in platelets in response to
insulin [8].
Conclusions
Our study focused on quantifying the effect of platelet-
derived NO on platelet adhesion and aggregation on a
surface in response to external factors (i.e. insulin, isopro-
terenol, and shear) and in the presence of whole blood.
Platelet-derived NO did not affect platelet adhesion at low
shear but had a significant effect at intermediate and high
shear. Production of NO in platelets was dominated by
receptor-mediated interactions at intermediate shear and
mechano-transduction at high shear. This study and
future work may lead to a better understanding of platelet-
derived NO and its role in healthy and diabetic vascular
wound healing.Thrombosis Journal 2004, 2:11 http://www.thrombosisjournal.com/content/2/1/11
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Methods
Materials
Low molecular weight heparin, HEPES, NaCl, collagen III
from calf skin, bovine serum albumin (BSA), L-nitro-
amine-methyl-ester (L-NAME), insulin from porcine pan-
creas, and isoproterenol were obtained from Sigma.
Recombinant hirudin (r-hirudin) was obtained from Pen-
tapharm and 1H-[1,2,4]oxadiazolo [4, 3-a]quinoxalin-1-
one (ODQ) was obtained from Cayman Chemical. Mepa-
crine (quinacrine) was obtained from ICN Biomedicals.
Fluorescein isothiocyanate (FITC) was generously
donated by Paul Friese, University of Oklahoma Health
Sciences Center, Oklahoma City, OK. The S12 anti-P-
selectin monoclonal antibody was generously donated by
Roger P. McEver, Oklahoma Medical Research
Foundation, Oklahoma City, OK. Glass cover slips (24 ×
50 mm) were obtained from Fisher Scientific.
Preparation of Glass Coverslips
Each cover slip was washed with 20 mL nanopure H2O
and 10 mL 95% ethanol. After washing was complete, the
cover slips were then placed in a 95% ethanol bath for at
least 12 hours. Before use, each cover slip was rinsed with
an additional 20 mL 95% ethanol and allowed to air-dry
for 15 minutes.
Protein coating of Cover slips
Collagen III solution was prepared at 0.8 mg/mL in 17
mM acetic acid (pH 2.6) at least 24 hours prior to use. BSA
solution was prepared at 0.1% in 10 mM HEPES/115 mM
NaCl buffer (pH 7.4). Half of each cover slip was coated
with collagen and allowed to incubate for 4 hours in a
humidified environment (80–90%) at room temperature
(~24°C). After incubation, each slide was rinsed with 10–
15 mL of HEPES/NaCl buffer solution to remove excess
collagen and coated with 0.1% BSA solution for at least 1
hour.
Platelet Preparation
Venous blood collected from healthy donors (30–60 mL,
depending on shear rate and length of experiment) was
anticoagulated with low molecular weight heparin to a
final concentration of 20 U/mL or r-hirudin to a final con-
centration of 40 anti-thrombin units/mL (ATU/mL). The
fluorescent dye mepacrine was then added to a final con-
centration of 10 µM and allowed to incubate for 10–15
minutes. All donors gave informed consent to participate
in our study according to methods approved by the Uni-
versity of Oklahoma Institutional Review Board.
Flow Experiments
The arterial flow environment was modeled with an in
vitro parallel plate flow chamber similar to those previ-
ously characterized [32,33]. The dimensions of the flow
channel were the 0.013 × 1.3 cm for experiments done at
a shear rate of 100 s-1, 0.013 × .8 cm for shear rate of 500
s-1, and 0.013 × .25 cm for shear rates of 1,000 and 2,000
s-1.
In some studies, 500 pM insulin or 100 µM isoproterenol
was added to the anti-coagulated blood 10 minutes before
the start of an experiment. In other studies, L-NAME, an
inhibitor of platelet NO synthesis was added at a
concentration of 200 µM for 20 minutes before the start
of an experiment. In additional studies, ODQ, an inhibi-
tor of guanylate cyclase was added at a concentration of
100 µM for 20 minutes before the start of an experiment
[18,19,34]. In still other studies, combinations of L-
NAME or ODQ and insulin or isoproterenol were added
as described above, except that L-NAME or ODQ was
added 20 minutes prior to insulin or isoproterenol addi-
tion. In each experiment, blood was perfused for 5 – 10
minutes.
In all studies, blood was used in experiments within two
hours of collection. The order of experiments was varied
randomly to insure that time-dependent platelet pheno-
type was not skewing the results. Additionally, flow cyto-
metric studies of platelets showed no significant change in
platelet activation, as measured by P-selectin expression,
over the course of 4 hours (data not shown).
Microscopy and Imaging Systems
A syringe pump provided the flow through the flow cham-
ber. The flow chamber was placed on the stage of a Nikon
Diaphot 300 inverted microscope. The illumination was
provided by a 75W Xenon light source passing through a
480 nm excitation filter and a 40 × fluorite objective lens.
The fluorescent emission from adherent platelets was
passed through a 514 nm filter and converted to analog
signal by an image intensifier and CCD camera. The image
was recorded on VHS tape for subsequent analysis. The
extent of mural thrombus formation on the surface was
quantified in terms of the percent coverage of a represent-
ative area of the collagen-coated surface at the interface
between the collagen and albumin. The analyzed area was
approximately 100 µm wide by 150 µm in the direction of
flow. Digital image analysis was performed on an SGI
Indy workstation running the ISEE® image analysis soft-
ware by Inovision. A background image was acquired after
blood began flowing over the surface but before adhesion
of any platelets. This image was subtracted from subse-
quent images. Platelets were identified based on size and
intensity using adjustable parameters. Images were
acquired and analyzed every 10–30 seconds over the
course of each experiment, which lasted from 5–10
minutes.Thrombosis Journal 2004, 2:11 http://www.thrombosisjournal.com/content/2/1/11
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Statistical Analysis
Statistical significance of the results was assessed with the
aid of the software package SPSS (version 11.5 for Win-
dows). The statistical tests used were the Post Hoc test for
multiple comparisons and the student's t-test. Results
were deemed significant if p < 0.05.
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